Evaluation of Potential Drug‐Drug Interaction Risk of Pexidartinib With Substrates of Cytochrome P450 and P‐Glycoprotein

Pexidartinib is approved for treatment of adults with symptomatic tenosynovial giant cell tumor. In vitro data showed pexidartinib's potential to inhibit and induce cytochrome P450 (CYP) 3A, inhibit CYP2C9, CYP2C19 and P‐glycoprotein (P‐gp). Herein, 2 open‐label, single‐sequence, crossover stud...

Descripción completa

Detalles Bibliográficos
Autores principales: Zahir, Hamim, Kobayashi, Fumiaki, Zamora, Cynthia, Gajee, Roohi, Gordon, Michael S., Babiker, Hani M., Wang, Qiang, Greenberg, Jonathan, Wagner, Andrew J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Drug Interactions
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7891582/
https://www.ncbi.nlm.nih.gov/pubmed/32918831
http://dx.doi.org/10.1002/jcph.1734

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7891582/
https://www.ncbi.nlm.nih.gov/pubmed/32918831
http://dx.doi.org/10.1002/jcph.1734

Ejemplares similares